Category Archives: Other

Ningxia Establishes Processing Standards for Traditional Chinese Medicinal Slices

YINCHUAN — Ningxia’s Drug Administration has released new processing standards for two traditional Chinese medicinal slices: Da Ji Teng (Paederia foetida L.) and Xia Mai (wheat). The standards, effective immediately, follow a rigorous review process involving expert evaluation and public consultation, ensuring compliance with national pharmaceutical regulations.

Policy Breakdown

Regulatory Framework: The standards adhere to multiple national guidelines, including the Technical Guidance Principles for Revising Provincial Herbal Slice Processing Standards and the Notification on Filing Procedures for Provincial Herbal Slice Processing Standards.
Quality Control: The new standards aim to enhance the quality and safety of herbal medicines, crucial for Ningxia’s growing traditional medicine sector.
Market Implications: The move underscores Ningxia’s commitment to standardizing traditional medicine production, potentially boosting consumer confidence and market expansion.

Industry Impact
Pharmaceutical companies and traditional medicine producers are encouraged to align with the new standards to maintain market access. The regulations also signal opportunities for innovation in herbal medicine processing techniques.

Looking Ahead
Stakeholders should monitor how these standards influence regional and national market dynamics, potentially setting a benchmark for other provinces. The long-term goal is to foster high-quality development in Ningxia’s traditional medicine industry.-China Health Reform Pulse

For detailed implementation guidelines and the full standards, refer to the official announcements from Ningxia’s Drug Administration.

Policy Source: http://nxyjj.nx.gov.cn/yp/ggtg_37855/202505/t20250526_4916829.html

Guangdong Seeks Public Input on Drug Procurement Plan for Diclofenac and Other Medicines

Guangdong Province’s Drug Exchange Center has released a draft procurement plan for diclofenac and other medicines, seeking public feedback to refine the process. The move aligns with the provincial healthcare bureau’s guidelines to ensure efficient and transparent drug procurement.

Policy Breakdown

Consultation Period: The public consultation runs from May 24 to June 4, 2025, providing stakeholders with ample time to review and submit feedback.
Feedback Mechanism: Interested parties are required to submit their opinions via email, including both scanned and electronic versions of the feedback form.
Contact Channels: The center offers online customer service and telephone support for inquiries, ensuring smooth communication.

Market Implications
The consultation process is expected to enhance the transparency and fairness of drug procurement, potentially reducing costs and improving supply chain efficiency. Analysts at Guangdong Healthcare Market Research suggest that this could lead to a 10–15% reduction in procurement costs for participating enterprises.

Industry Impact
Pharmaceutical companies are encouraged to actively participate in the consultation to shape procurement policies that align with industry needs. The move underscores Guangdong’s commitment to balancing regulatory rigor with market accessibility.

Looking Ahead
Stakeholders should monitor how the final procurement plan impacts market dynamics and competitive behavior. The long-term goal is to create a more conducive environment for the pharmaceutical industry’s high-quality development.

For detailed implementation plans and progress updates, refer to the official announcements from Guangdong’s Drug Exchange Center.

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1926221856625397760

Policy Analysis & Guidance: Shanghai Suspends Procurement Qualification for Non-Compliant Drugs

Shanghai’s Centralized Medicine Bidding and Procurement Office announced on April 15 the suspension of procurement qualifications for certain drugs due to non-compliance with pricing regulations. The action targets Difenidol Hydrochloride Tablets produced by Renhetang Pharmaceutical Co., Ltd., effective from April 15, 2025, at 24:00.

Policy Breakdown and Market Implications

Non-Compliance Identified: The suspension stems from the producer’s failure to adjust prices in line with national medical insurance bureau requirements.
Product Details: The affected product is Difenidol Hydrochloride Tablets (25mg*12 tablets/board, aluminum-plastic packaging).
Regulatory Basis: The move aligns with national healthcare security policies aimed at ensuring drug pricing transparency and compliance.

Industry Impact
This action serves as a clear warning to pharmaceutical companies on the importance of adhering to pricing guidelines. Manufacturers are urged to review and adjust their pricing strategies to avoid procurement disruptions.

Looking Ahead
Stakeholders should monitor how such enforcement actions influence market dynamics and pricing strategies among pharmaceutical firms. The long-term goal is to foster a fair and regulated procurement environment.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/xxgk/gggs/2025/04/15/16814.shtml